Endoscopic Ultrasound Guided Tissue Sampling (The SharkBITE Study) — SharkBITE  

Pancreas Cancer Clinical Trial

Official title: SharkCore Biopsy Needle Versus Standard FNA Needle in the Diagnosis of Solid Pancreatic Masses a Randomised Controlled Cross-over Trial of EUS Guided Tissue Acquisition - The SharkBITE Study

Status Completed

Clinical Trial Summary

This study compares the diagnostic performance of Endoscopic ultrasound (EUS) guided fine needle aspiration and EUS guided core biopsy (SharkCore) in patients with a solid pancreatic mass.

Clinical Trial Description

Endoscopic ultrasound (EUS) guided fine needle aspiration (FNA) and fine needle biopsy (FNB) are the standard methods for obtaining tissue samples from tumours of the pancreas. The diagnostic accuracy by strict criteria is around 75-80%. A non diagnostic sample causes delay and the need for a repeat procedure. To date no significant difference has been found between standard FNA and standard FNB needles. A novel opposing bevel design (SharkCore) needle for FNB may provide better diagnostic performance. The aim of this study is to compare the performance of a standard needle and the Sharkcore needle. Patients attending for routine biopsy of a suspected pancreatic tumour will be invited to participate. All participants will have 3 samples taken with each needle. The samples from each needle will be processed and reported separately with the pathologists blinded as to the report from the other needle. Following the procedure participants will be observed as normal in the recovery area and allowed home later. Further study participation is limited to 1 telephone call at 7 days. Participants will be asked if they have developed any new symptoms since the procedure and whether they have had to seek medical attention for this.The risks of the study procedure are the same as those of a non study procedure. Both needle types are in routine use in our unit. The study will be performed in the endoscopy unit of the Freeman hospital. The study is funded by a grant from Medtronic the company who make the Sharkcore needle. The study is planned to recruit 108 participants over 10 months with a further 6 months of follow up. If the new needle is found to perform better its routine use will potentially reduce the delay experienced by patients as well as the cost incurred by repeat procedures. ;

Related Conditions & MeSH terms

• Adenocarcinoma
• Chronic Pancreatitis
• Neoplasms
• Pancreas Adenocarcinoma
• Pancreas Cancer
• Pancreas Neoplasm, Benign
• Pancreatic Neoplasms
• Pancreatitis
• Pancreatitis, Chronic

• NCT number: NCT03532347
• Study type: Interventional
• Source: Newcastle-upon-Tyne Hospitals NHS Trust
• Status: Completed
• Phase: N/A
• Start date: May 22, 2017
• Completion date: November 4, 2018